Brief: Daré Bioscience Announces Additional Positive Data From Phase 2B Respond Study

Dare Bioscience

01/11/2023 12:05

Nov 1 (Reuters) - Dare Bioscience Inc  DARE.O :
    * DARÉ BIOSCIENCE ANNOUNCES ADDITIONAL POSITIVE DATA FROM
PHASE 2B
RESPOND STUDY OF SILDENAFIL CREAM, 3.6% IN WOMEN AND PROPOSED
ENDPOINTS AND PATIENT POPULATION FOR PHASE 3 PROGRAM
    * DARE BIOSCIENCE INC - COMPANY IS ON TRACK FOR END OF PHASE
2
MEETING WITH FDA THIS YEAR
    * DARE BIOSCIENCE INC - DATA SUPPORT ADVANCING CO-PRIMARY
ENDPOINTS AND SELECTED PATIENT POPULATION FROM PHASE 2B TO
PROPOSED PHASE 3 PROGRAM

Source text for Eikon:  ID:nGNX14XzPN 
Further company coverage:  DARE.O 

 ((Reuters.Briefs@thomsonreuters.com;))